Amgen-AstraZeneca Experimental Asthma Drug Surprisingly Flops in Phase III

An investigational asthma treatment under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids in a Phase III study.

On Monday, the two companies said the investigational asset tezepelumab did not meet its primary endpoint in the Phase III SOURCE trial assessing the drug’s ability to generate a statistically significant reduction of corticosteroid use on top of standard of care treatment in some asthma patients.